Is stem cell transplantation still needed for adult Philadelphia chromosome-positive acute lymphoblastic leukemia receiving tyrosine kinase inhibitors therapy?: A systematic review and meta-analysis.
<h4>Background</h4>Hematopoietic stem cell transplantation (HSCT) is the current mainstay treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). However, tyrosine kinase inhibitors (TKI) also play a significant role in the treatment of these patients. We c...
Main Authors: | Ben Ponvilawan, Smith Kungwankiattichai, Nipith Charoenngam, Weerapat Owattanapanich |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0253896 |
Similar Items
-
Vitamin D and uric acid: Is parathyroid hormone the missing link?
by: Ben Ponvilawan, et al.
Published: (2021-09-01) -
TYROSINE KINASE INHIBITORS PLUS HYPER-CVAD FOR THE FRONTLINE TREATMENT OF PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
by: R.D. Portugal, et al.
Published: (2020-11-01) -
Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL)
by: Khadra Salami, et al.
Published: (2013-03-01) -
Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis
by: Ben Ponvilawan MD, et al.
Published: (2021-08-01) -
Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
by: Hong Hoe Koo
Published: (2011-03-01)